Barely a month after Hyderabad-based Dr. Reddy's Lab started Ph-3 trials for its Coronavirus (COVID-19) vaccine - Sputnik -V, it has applied for emergency use
Improving Covishield efficiency
Updated:
Updated:
February 08, 2021 23:11 IST
There are big benefits in delaying the second dose to 12 weeks and starting the first dose for the elderly and vulnerable
Share Article
AAA
A healthworker shows a vial of Covishield vaccineat the Government Royapettah Hospital in Chennai. . | Photo Credit: JOTHI RAMALINGAM B
There are big benefits in delaying the second dose to 12 weeks and starting the first dose for the elderly and vulnerable
On January 16, large-scale vaccination of healthcare workers began across India. Two vaccines are in use Covishield and Covaxin both rolled out under emergency use authorisation (EUA) by the Drugs Controller General of India (DCGI), with the condition that all information on adverse reactions following immunisation (AEFI) be collected. For Covishield, the responsibility of AEFI monitoring is with the Government of India, since the authorisation for restricted use is at the discretion of the governme
In a statement, Pfizer said it had decided to withdraw the application after a meeting with the Drug Regulatory Authority of India on 3 Feb, in which the regulator stated that there may be need for additional information
Don’t doubt Indian vaccines
Updated:
Updated:
Vaccination is important to prevent a second wave
Share Article
AAA
Vaccination is important to prevent a second wave
Several people have questioned the emergency approval given to the indigenously developed COVID-19 vaccine. They have demanded efficacy data and cast aspersions on the regulatory machinery. Such views will only increase vaccine hesitancy.
It is not the case that the vaccine developed indigenously is being pushed by vested interests, while the international vaccines are great. Questions have been raised about the Moderna and Pfizer vaccines too, which have reported more than 90% efficacy. As Peter Doshi wrote in